Sold as Vivjoa. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Oteseconazole (sold as Vivjoa), first approved Apr 26, 2022, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vivjoa | Part D | $539K | +67% | 147 |
| Platform Trial for Salvage Consolidation Therapy in Dimorphic FungiCoccidioidomycosis, Blastomycosis · University of Minnesota | Phase 2 | Not yet recruiting | Sep 4, 2026 |
| Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）Vulvovaginal Candidiasis · Beijing Tsinghua Chang Gung Hospital | — | Not yet recruiting | Jul 1, 2025 |
| Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)Hiv, Cryptococcal Meningitis · David Boulware | Phase 2 / Phase 3 | Recruiting | Oct 30, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 26, 2022 | VivjoaNDA 215888 · New molecular entity | Mycovia Pharms | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
